These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
574 related articles for article (PubMed ID: 24374933)
1. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933 [TBL] [Abstract][Full Text] [Related]
2. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877 [TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53. Simões ML; Hockley SL; Schwerdtle T; Gamboa da Costa G; Schmeiser HH; Phillips DH; Arlt VM Toxicol Appl Pharmacol; 2008 Oct; 232(1):86-98. PubMed ID: 18639569 [TBL] [Abstract][Full Text] [Related]
4. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952 [TBL] [Abstract][Full Text] [Related]
5. CKIα ablation highlights a critical role for p53 in invasiveness control. Elyada E; Pribluda A; Goldstein RE; Morgenstern Y; Brachya G; Cojocaru G; Snir-Alkalay I; Burstain I; Haffner-Krausz R; Jung S; Wiener Z; Alitalo K; Oren M; Pikarsky E; Ben-Neriah Y Nature; 2011 Feb; 470(7334):409-13. PubMed ID: 21331045 [TBL] [Abstract][Full Text] [Related]
6. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer. Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916 [TBL] [Abstract][Full Text] [Related]
7. TP53 mutations, expression and interaction networks in human cancers. Wang X; Sun Q Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943 [TBL] [Abstract][Full Text] [Related]
8. Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. Fischer M; Grossmann P; Padi M; DeCaprio JA Nucleic Acids Res; 2016 Jul; 44(13):6070-86. PubMed ID: 27280975 [TBL] [Abstract][Full Text] [Related]
9. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Mao JH; Perez-Losada J; Wu D; Delrosario R; Tsunematsu R; Nakayama KI; Brown K; Bryson S; Balmain A Nature; 2004 Dec; 432(7018):775-9. PubMed ID: 15592418 [TBL] [Abstract][Full Text] [Related]
10. Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas. Chen H; Huang H; Zhao J; Wang Z; Chang M; Xue L; Zhu W; Chai Y; Li G; Wang Z; Wu H J Neurooncol; 2019 Jul; 143(3):369-379. PubMed ID: 31049827 [TBL] [Abstract][Full Text] [Related]
11. Intratumour heterogeneity of p53 expression; causes and consequences. Xue Y; San Luis B; Lane DP J Pathol; 2019 Nov; 249(3):274-285. PubMed ID: 31322742 [TBL] [Abstract][Full Text] [Related]
12. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005 [TBL] [Abstract][Full Text] [Related]
13. Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. Bieging-Rolett KT; Kaiser AM; Morgens DW; Boutelle AM; Seoane JA; Van Nostrand EL; Zhu C; Houlihan SL; Mello SS; Yee BA; McClendon J; Pierce SE; Winters IP; Wang M; Connolly AJ; Lowe SW; Curtis C; Yeo GW; Winslow MM; Bassik MC; Attardi LD Mol Cell; 2020 Nov; 80(3):452-469.e9. PubMed ID: 33157015 [TBL] [Abstract][Full Text] [Related]
15. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features. Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602 [TBL] [Abstract][Full Text] [Related]
16. Mutated Li AM; Boichard A; Kurzrock R Cancer Biol Ther; 2020; 21(1):95-100. PubMed ID: 31564192 [TBL] [Abstract][Full Text] [Related]
17. Characterizing genomic differences of human cancer stratified by the TP53 mutation status. Wang M; Yang C; Zhang X; Li X Mol Genet Genomics; 2018 Jun; 293(3):737-746. PubMed ID: 29330617 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes. Khan R; Pari B; Puszynski K Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790205 [TBL] [Abstract][Full Text] [Related]
19. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors. Ganci F; Conti S; Fontemaggi G; Manciocco V; Donzelli S; Covello R; Muti P; Strano S; Blandino G; Spriano G OMICS; 2011 Jun; 15(6):375-81. PubMed ID: 21348641 [TBL] [Abstract][Full Text] [Related]
20. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Song H; Hollstein M; Xu Y Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]